We'd like to know what you think! Participate in our Integrated Diabetes Services monthly survey.
Answer our type 1 diabetes trivia question and win a free book!
Integrated Diabetes Services is excited to announce the addition of Alicia Downs RN, BSN, CDE to our clinical team. Alicia will oversee IDS’s patient care and education services through our main office in Wynnewood, PA.
Recognizing that our ultimate goal at Integrated Diabetes Services is to help our clients live healthier, happier lives, we cannot overstate the importance of sound emotional health. Diabetes places an emotional and physical strain on all of us (patients, caregivers, and yes, even healthcare providers!), putting us at high risk for a number of mental health complications. To address this need, we have partnered with one of the best in the business: Dana Lehman, Psy. D.
50 year study of people with diabetes confirms that physical activity is not something diabetics can avoid! The benefits are life changing both in the short term and the long term.
Dexcom partners with Fitbit to bring CGM data together with a leading fitness tracker, adding new social dimensions to blood glucose monitoring
A new study led by researchers in the University of Toronto's Institute of Biomaterials & Biomedical Engineering (IBBME), transplanted healthy pancreatic cells under the skin to see if they would produce insulin for blood glucose control.
While noninsulin medications were not developed specifically for type 1 diabetes, they could in fact play an important role in management.
An early research study suggests that imatinib, which is a drug that suppresses the immune system , may help to preserve some beta cell function in people who are recently diagnosed with Type 1 diabetes. Imatinib, a tyrosine kinase inhibitor, is already approved for use in the treatment of Chronic Myelogenous Leukemia (CML) and several other cancers.
The European Association for the Study of Diabetes 2017 annual meeting will take place in Lisbon, Portugal from September 11-15, 2017. Some interesting research on Type 1 diabetes is on tap for the meeting, so here's a sneak preview!
Do you tend to bolus for your meal or snack during or after eating? If so, you may be unwittingly getting in your own way.
Although it didn't work wonders for blood glucose (BG) levels, liraglutide improved anthropometric and metabolic parameters without causing an increase in hypoglycemia, according to the results of a clinical trial published in July in Diabetes, Obesity, and Metabolism.
Have you ever noticed when you look at your lab results, there's a measure of kidney function called eGFR that is reported for both non-African American, and for African American? That's because there are racial and ethnic differences in kidney function decline. When it comes to A1c levels, they are higher in black people than in white people. It is debatable if this is because of poorer glycemic control, or whether there are, in fact, differences between the races in the glycation of hemoglobin.
Sotagliflozin is a drug in development, under investigation by Lexicon Pharmaceuticals and Sanofi. It is a first-in-class, oral dual inhibitor of sodium-glucose cotransporter types 1 and 2 (SGLT1 and SGLT2).
New research shows promise in keeping beta cell insulin production stable in those with newly diagnosed type 1 diabetes.